Podocytes Globotriaosylceramide Content as a Potential Biomarker for Early Monitoring the Efficacy of Enzyme Replacement Therapy in Fabry Disease

Editorial

Austin Renal Dis. 2016; 1(1):1004.

Podocytes Globotriaosylceramide Content as a Potential Biomarker for Early Monitoring the Efficacy of Enzyme Replacement Therapy in Fabry Disease

Pozdzik A¹* and Brocheriou I2,3

¹Nephrology and Dialysis Department, Centre Hospitalier Chrétien - Clinique Saint-Joseph, Liège, Belgium

²Pathology Department, AP-HP Pitié Hospital, Paris, France

³UPMC Univ-Paris 6, Paris, France

*Corresponding author: Agnieszka POZDZIK, Nephrology and Dialysis Department, Centre Hospitalier Chrétien - Clinique Saint-Joseph, Rue de Hesbaye, 75, B-4000 Liège, Belgium

Received: October 03, 2016; Accepted: October 06, 2016; Published: October 10, 2016

Editorial

Fabry Disease (FD) is an inherited X-linked lysosomial storage disorder secondary to the mutation of alpha-galactosidase (αGAL) gene [1]. The αGAL gene impairment results in various defects of αGAL enzymatic activity ranging from slight decrease of the amount of enzyme to its complete absence. FD is mainly described in men. However, women could be also affected, sometimes, with the same degree of severity. This can be explained by sporadic “de novo” mutations [2,3] of αGAL or by the inactivation of unaltered X-chromosome in heterozygous carriers. Therefore, the careful screening for this disease in all suspected female patients without any familial context is also strongly suggested (Figure 1) [4].

Citation: Pozdzik A and Brocheriou I. Podocytes Globotriaosylceramide Content as a Potential Biomarker for Early Monitoring the Efficacy of Enzyme Replacement Therapy in Fabry Disease. Austin Renal Dis. 2016; 1(1): 1004.